InvestorsHub Logo
Followers 45
Posts 4190
Boards Moderated 0
Alias Born 09/01/2017

Re: IkeEsq post# 474271

Monday, 05/16/2022 3:51:09 PM

Monday, May 16, 2022 3:51:09 PM

Post# of 687334
Should it not be reasonable to address the slides in the presentation detailing the pfs to OS endpoint change once it was learned that pseudo progressive is a result of immunotherapy and indicative of anti tumor action?

As well as the clearly stated performance against the primary and secondary endpoints of OS?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News